Cite
HARVARD Citation
Lan, C. et al. (2018). Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet oncology. 19 (9), pp. 1239-1246. [Online].